DX5 Stock Chart & Stats
€7.85
€0.30(4.11%)
At close: 4:00 PM EST
€7.85
€0.30(4.11%)
Day’s Range― - ―
52-Week Range€7.40 - €12.60
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€50.79M
Enterprise Value€47.48M
Total Cash (Recent Filing)€0.00
Total Debt (Recent Filing)€112.00K
Price to Earnings (P/E)5.7
Beta0.37
Next Earnings
Aug 20, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.82
Shares Outstanding5,838,224
10 Day Avg. Volume1
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.60
Price to Sales (P/S)146.07
P/FCF Ratio-121.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.20Price Target Upside157.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.18
Revenue Forecast (FY)€10.24M
Bulls Say, Bears Say
Bulls Say
Clinical Validation And Customer AdoptionExtensive clinical validation backed by peer‑reviewed studies and tens of thousands of performed tests, together with new customer wins at multiple medical centers, supports broad clinical applicability and clinician confidence in the device.
Product Innovation And Workflow ImprovementThe handheld blood volume analyzer delivers lab‑grade precision with faster turnaround and substantially reduced blood requirements, improving portability and streamlining clinical workflow for office‑based testing.
Regulatory And Market AccessA planned CLIA waiver submission for moderate‑complexity testing could allow use in non‑CLIA labs and nontraditional care settings, expanding the addressable market and facilitating more physician office activations.
Bears Say
Investment Structure And ValuationThe company's designation as a specific investment fund structure has reduced visibility among traditional investors and may be suppressing its valuation despite operational progress.
Operating Losses From R&D And CommercializationOperating division losses driven by investments in research, development, and commercial capabilities for the next‑generation analyzer increase cash burn and place pressure on near‑term profitability.
Daxor News
DX5 FAQ
What was Daxor Corp’s price range in the past 12 months?
Daxor Corp lowest stock price was €7.40 and its highest was €12.60 in the past 12 months.
What is Daxor Corp’s market cap?
Daxor Corp’s market cap is €50.79M.
When is Daxor Corp’s upcoming earnings report date?
Daxor Corp’s upcoming earnings report date is Aug 20, 2026 which is in 46 days.
How were Daxor Corp’s earnings last quarter?
Daxor Corp released its earnings results on Mar 03, 2026. The company reported €1.617 earnings per share for the quarter, beating the consensus estimate of N/A by €1.617.
Is Daxor Corp overvalued?
According to Wall Street analysts Daxor Corp’s price is currently Undervalued.
Does Daxor Corp pay dividends?
Daxor Corp does not currently pay dividends.
What is Daxor Corp’s EPS estimate?
Daxor Corp’s EPS estimate is -0.03.
How many shares outstanding does Daxor Corp have?
Daxor Corp has 5,838,224 shares outstanding.
What happened to Daxor Corp’s price movement after its last earnings report?
Daxor Corp reported an EPS of €1.617 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Daxor Corp?
Currently, no hedge funds are holding shares in DE:DX5
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Daxor Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€20.20 (157.38% Upside)
€20.20 (157.38% Upside)
Insider Transactions
Bought Shares
Worth €7.9K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
51.13%
12-Months-Change
Fundamentals
Return on Equity
22.50%
Trailing 12-Months
Asset Growth
25.60%
Trailing 12-Months
Company Description
Daxor Corp
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
DX5 Stock 12 Month Forecast
Average Price Target
€20.20
▲(157.38% Upside)
Technical Analysis
Options Prices
Currently, No data available
---